Friday, May 13, 2022 8:15:16 AM
Hi Cherry Tree,
ABeta's number from Project Brain Cancer show 0 survivor with SOC at 60 month. Zero. Whatever the state, the original number, big or small. Zero.
All the slides from the study show two things: for SOC/External Data:
* At Risk Patients: 0, for all categories
* KM Curve: some non events still pushing the KM curve (5% for one, etc.)
Now if it's 0 at risk, it means *all* the KM curve for that point are made of LTFU. All of them.
My contention, given abeta's numbers, is that they are all dead. It's an awful disease. SOC, think Chemo side effects, and at 5 years, you are dead.
I made the same assumption for the DCVax numbers: All LTFU are dead. Now, DCVax AtRisk patients (ALIVE) is 25 for one, etc. So a significant difference.
DCVax is the only hope at this stage.
ABeta's number from Project Brain Cancer show 0 survivor with SOC at 60 month. Zero. Whatever the state, the original number, big or small. Zero.
All the slides from the study show two things: for SOC/External Data:
* At Risk Patients: 0, for all categories
* KM Curve: some non events still pushing the KM curve (5% for one, etc.)
Now if it's 0 at risk, it means *all* the KM curve for that point are made of LTFU. All of them.
My contention, given abeta's numbers, is that they are all dead. It's an awful disease. SOC, think Chemo side effects, and at 5 years, you are dead.
I made the same assumption for the DCVax numbers: All LTFU are dead. Now, DCVax AtRisk patients (ALIVE) is 25 for one, etc. So a significant difference.
DCVax is the only hope at this stage.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
